In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bio-Techne Corp.

www.bio-techne.com

Latest From Bio-Techne Corp.

Breakthrough Status, Big Investments For Liquid Biopsies

The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.

Diagnostics Commercial

Market Intel: Liquid Biopsy II – Emerging Companies Look For Liquid Gold

The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.

Cancer Personalized Medicine

Market Intel: Liquid Biopsy I – Analyzing Market Landmarks And Landmines

The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.

Cancer In Vitro Diagnostics

M&A Analysis: Dealmaking Simmers In June

Medtech M&A activity waned in June, with the market showing signs of a summer slump. Twelve acquisitions were announced and closed during the month, a dip in activity compared to the 21 deals recorded in the same period last year, and the 17 recorded in May.

M & A Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register